Charles J. Lager, Managing Director
Prior to forming LynxCom Partners, Mr. Lager served as Executive Vice President for LifeCare Solutions after selling the company to a new investment group. Mr. Lager served as the President & Chief Executive Officer and Director of LifeCare Solutions, Inc. from August, 2000 through July 2003. Prior to that he held the position of Executive Vice President of Home Medical of America, Inc. from June 1999 through August, 2000.
Mr. Lager was one of the founders of Nations Healthcare, Inc. and served as a member of the Board of Directors from 1993 through 1999. He held the following positions with Nations: President & CEO, Executive Vice President, Business Development and Chief Compliance Officer. Prior to that Mr. Lager also was a founder of LifeCare Solutions, Inc. and served as the President & CEO and Director from 1987 through 1993.
Mr. Lager has 20 years of home care experience and over 30 years of health care experience. He has held Directorships with professional and industry associations, the most recent being a member of the Board of Directors of the California Association of Health Services at Home (CAHSAH) from 1992 through 1999. He has also served on the Board of Directors of Triad Medical, Inc. He currently serves on the Board of Directors of the Community Health Accreditation Program, Inc. (CHAP) based in Washington DC. Mr. Lager received his M.B.A. in Financial Management from National University and his B.S. in Pharmacy from the University of Arizona.
Julie B. Decker, Managing Director
Julie Decker has been a senior level healthcare executive for the past 12 years. The scope of her experience includes national sales responsibility, operations, company turnarounds, and mergers and acquisitions for leading healthcare companies. Prior to joining FocalPoint as an operating partner, Ms. Decker held the position of Senior Vice President of Sales for Crescent Healthcare, a national pharmacy provider. She was responsible for both the acute and chronic divisions, as well the development of ambulatory infusion centers. Recognizing the importance of pharmaceutical partnerships, Ms. Decker has built alliances with major manufacturers and distributors. She has been integral in lobbying CMS and Congress for higher physician reimbursement and extended Medicare coverage.
Prior to January 2003, Ms. Decker spent eight years at Nations Healthcare (“NHC”) and it’s successors as a Senior Vice President of Sales and Operations. NHC was an infusion pharmacy, respiratory, home health nursing and durable medical equipment company which contributed to Ms. Decker’s expertise in the integrated delivery model. While at NHC she led due diligence teams through several mergers, acquisitions and company consolidations. She had P&L responsibility for the Pacific Region and Midwest territories which generated a net revenue of $120 million. Ms. Decker’s responsibilities extended to commercial payers and she implemented a managed care matrix of over 300 contracts to leverage statewide and national networks.
Ms. Decker also established a Medicare certified hospice and home health program in Southern California with multi-site locations. In 1996, she established a hospice Foundation that continues to operate and until 2004 she served on the San Diego Hospice Board of Directors.
A Massachusetts native, Ms. Decker earned her BA degree, cum laude, from Alaska Pacific University, and is a graduate of UC San Diego’s Healthcare Executive Leadership Program. Her current and past professional affiliations include the Bioethics Committee of Scripps Memorial Hospital, San Diego Women’s Healthcare Administrators, Adaptive Business Leaders Roundtable, and First Opinion E-Health Technologies.
Bruce A. Huebner, Managing Director
Mr. Huebner comes to LynxCom Partners with over 35 years of experience in the medical diagnostics/biotechnology industry. Prior to joining LynxCom, Mr. Huebner served as President of Osmetech Molecular Diagnostics, where he was active in the acquisition of Clinical Micro Sensors from Motorola and managed the integration of the CMS business into the Osmetech organization. Mr. Huebner was instrumental in transforming Osmetech into a fully functional molecular diagnostics business which obtained FDA clearances for four new products over a three year period. Before joining Osmetech, Mr. Huebner was President and Chief Operating Officer of Nanogen Inc., a publicly held nanotechnology/microarray technology company based in San Diego. He had responsibility for all aspects of business which included research & development, sales and marketing, operations, quality, customer service, human resources and legal.
Mr. Huebner was also employed by Gen-Probe, Inc. for nearly 10 years, where he held positions as Executive Vice President and Chief Operating Officer and Vice President of Marketing and Sales. During Mr. Huebner’s tenure the business grew from $42 million to over $150 million in revenue and grew from approximately 250 employees to over 700 employees.
Mr. Huebner’s other experience includes Vice President of Marketing and Sales at Quidel, Director of Marketing for the U.S. and Director of Marketing and Market Development in Europe for Hybritech, Inc., and various sales and marketing positions at Roche Diagnostics. Mr. Huebner has served as a member of the Biomedical Marketing Association, Medical Marketing Association, BioCom, Health Industry Manufacturers Assembly (HIMA), and Connect. He served as a Director on the Gen-Probe Board of Directors and was a Managing Director on the Osmetech, plc. Board.
James R. Glynn, Director
James R. Glynn has served as a Director of Alphatec Holdings and Alphatec Spine since May 2007. From January 2003 to July 2003, Mr. Glynn served as the President and interim Chief Executive Officer of Invitrogen Corp., a publicly held biotechnology company (Nasdaq:IVGN). Mr. Glynn retired from such positions in July 2003. From July 2002 to December 2002, Mr. Glynn was an Executive Vice President at Invitrogen, and from June 1998 to June 2002, he served as Invitrogen's Executive Vice President and Chief Financial Officer. From June 1998 to April 2006 Mr. Glynn served as a member of the board of directors of Invitrogen. From July 1995 to May 1997, he served as Senior Vice President and Chief Financial Officer. From May 1997 to July 1999, he served as the as Chief Operating Officer, Chief Financial Officer and a member of the board of directors of Matrix Pharmaceutical, Inc., a company focusing on the treatment of cancer. Mr. Glynn is currently a member of the board of directors of WebSideStory, Inc. a publicly held internet analytics company (Nasdaq:WSSI). Mr. Glynn holds a B.B.A. degree in accounting from Cleveland State University.
Laura L. Boxley, Senior Analyst
Laura Boxley joins LynxCom Partners as a specialist in program development, operations and regulatory compliance in the alternate site sector. Prior to joining LynxCom, Ms. Boxley served as Payer Program Manager for Pharmaceutical Buyers, Inc., a group purchasing organization based in Colorado. She was responsible for educating PBI member pharmacies on new regulatory developments, including the implementation of Medicare Part D, the Competitive Acquisition Program, and competitive bidding for DME suppliers. As Project Manager for PBI-subsidiary, Specialty Pharmacy Infusion and Injectable Network, Ms. Boxley developed the project plan and oversaw the pilot of an innovative fee-for-service dispensed data product.
Prior to November 2005, Ms. Boxley managed the ambulatory infusion center program at Crescent Healthcare, a California- based infusion pharmacy company, with responsibility over both the physician office and hospital outpatient programs.
Ms. Boxley holds a BS in Pharmacology, summa cum laude, from the University of California, Santa Barbara.
Matthew Lager, Information Technology
Matt provides technical development and consulting services related to web development, reporting, and data management.